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Objective: The goal of this study was to measure functional and structural aspects of local 32 
neuroinflammation induced by intracerebral injection of lipopolysaccharide (LPS) in rats using TSPO 33 
microPET imaging with [18F]DPA-714, magnetic resonance imaging (MRI), in vitro autoradiography 34 
and immunohistochemistry (IHC) in order to characterize a small animal model for screening of new 35 
PET tracers targeting neuroinflammation.  36 
 37 
Methods: Rats were injected stereotactically with LPS (50 µg) in the right striatum and with saline in 38 
the left striatum. [18F]DPA-714 microPET, MRI, in vitro autoradiography and IHC studies were 39 
performed at different time points after LPS injection for 1 month.   40 
 41 
Results: Analysis of the microPET data demonstrated high uptake of the tracer in the LPS injected site 42 
with an affected-to-non-affected side binding potential ratio (BPright-to-left) of 3.0 at 3 days after LPS 43 
injection. This BP ratio decreased gradually over time to 0.9 at 30 days after LPS injection. in vitro 44 
autoradiography ([18F]DPA-714) and IHC (CD68, GFAP and TSPO) confirmed local 45 
neuroinflammation in this model. Dynamic contrast enhanced (DCE) MRI demonstrated BBB 46 
breakdown near the LPS injection site at day 1, which gradually resolved over time and was absent at 47 
1 month after LPS injection.  48 
 49 
Conclusion: The LPS model is useful for first screening of newly developed tracers because of the 50 
easy design and the robust, unilateral inflammatory reaction allowing the use of the contralateral 51 
region as control. Additionally, this model can be used to test and follow up the benefits of anti-52 
inflammatory therapies by non-invasive imaging. 53 
 54 
 55 
 56 
 57 
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1. Introduction 58 
Neuroinflammation is the inflammation associated to with central nervous system (CNS) 59 
pathologies including Parkinson’s disease (PD), Alzheimer’s disease (AD), stroke, multiple sclerosis 60 
(MS), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), viral/bacterial infection, 61 
neoplasia and head trauma. These diseases trigger a cerebral immune activation which can lead to both 62 
collateral damage to brain tissue as well as neuroregeneration [1]. Microglia are resident CNS cells 63 
that have phenotypic similarities and functions to macrophages and constitute up to 10% of the total 64 
cell population of the brain. Microglia are plastic cells that show phenotypic changes in response to 65 
environmental signals, and can exert either neuroprotective or neurotoxic roles depending on the 66 
context.  67 
The most studied imaging biomarker of neuroinflammation is the translocator protein  (TSPO) 68 
[2] receptor or peripheral benzodiazepine receptor (PBR) that is expressed on the outer mitochondrial 69 
membrane of microglia and macrophages [3]. TSPO plays a crucial role in neurosteroidogenesis 70 
important during brain development and normal functioning during adulthood [3]. In the central 71 
nervous system, TSPO expression is low under healthy circumstances. However, in response to 72 
neuronal insults, TSPO expression increases mainly in microglia and astrocytes as detected in several 73 
neurodegenerative diseases such as PD, ALS, HD and AD [3]. The role of TSPO in regulation of 74 
neuroinflammation still remains to be elucidated. While TSPO antagonists can attenuate inflammation, 75 
a recent study of Bae et al. [4] suggested that TSPO is a negative regulator of neuroinflammation in 76 
microglia. TSPO has been identified as a valuable imaging biomarker for neuroinflammation since the 77 
degree of TSPO upregulation in response to injury is correlated with the degree of damage in 78 
neuroinflammation [5]. [18F]DPA-714 is a specific radiotracer for TSPO and has already been 79 
successfully evaluated in several animal models of neuroinflammation [6–8], in healthy humans [9] 80 
and ALS patients [10]. Recently, Owen et al. [11] reported a human TSPO polymorphism with a 81 
trimodal distribution in binding affinity (high-affinity, low-affinity and mixed affinity binders) for 82 
several TSPO ligands. The consequence of this polymorphism is that knowledge of binding status is 83 
needed to correctly quantify TSPO expression using these PET ligands in humans [11]. In the present 84 
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study, we used [18F]DPA-714 to characterize TSPO expression in a rat model of acute, local 85 
neuroinflammation induced by lipopolysaccharide (LPS). LPS is found in the outer membrane of 86 
gram-negative bacteria and activates Toll-like-receptor 4 (TLR4) mainly expressed by microglia and 87 
macrophages. TLR4 activation induces signal transduction pathways that regulate diverse 88 
transcriptional and posttranscriptional processes involved in inflammation [12]. Moon et al. [13] used 89 
the LPS model to compare [11C]PBR28 with their newly synthesized [18F]fluoromethyl-PBR28, while 90 
Dickens et al. [14] used the LPS model to compare [11C]PK11195 and [18F]GE-180. However, only 91 
one time point after LPS injection was studied to compare different TSPO tracers in these previous 92 
reports. The goal of the current study was to fully characterize the LPS rat model longitudinally with 93 
an established neuroinflammation tracer [18F]DPA-714, magnetic resonance imaging (MRI) and 94 
immunohistochemistry (IHC) to assess the dynamics of the neuroinflammatory reaction. This model 95 
will be used for screening of newly developed PET radiotracers as putative biomarkers of 96 
neuroinflammation. 97 
 98 
2. Material and methods 99 
a. LPS-induced neuroinflammation rat model 100 
An acute rat model of neuroinflammation was developed using lipopolysaccharide (LPS; E. 101 
Coli 055:B5; Sigma Aldrich, St. Louis, MO, USA). Female Wistar rats (250 - 300 g; 2 months old) 102 
were kept under gas anesthesia (2.5% isoflurane in O2 at a flow rate of 1 L/min) and positioned in a 103 
stereotactic head frame (Stoelting, Wood Dale, IL, USA). A small hole was drilled in the skull at the 104 
appropriate location using Bregma as reference. Neuroinflammation was induced by injecting 50 µg 105 
LPS dissolved in 4 µl of sterile NaCl 0.9% at the following coordinates: +0.5 mm antero-posterior, 3 106 
mm lateral (right hemisphere), 5.5/4.5 mm dorsoventral. After injection of 2 µl, the needle was 107 
retracted for 1 mm dorsoventral and another 2 µl was injected. The needle was left in place for an 108 
additional 10 min before being slowly withdrawn from the brain. The contralateral side was injected as 109 
control with 4 µl of sterile 0.9% NaCl solution. Animals (N=27) were housed in individually 110 
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ventilated cages in a thermoregulated (~22 °C), humidity-controlled facility under a 12 h/12 h 111 
light/dark cycle with access to food and water ad libitum. All animal experiments were conducted 112 
according to the Belgian code of practice for the care and use of animals, after approval from the local 113 
University Ethics Committee for Animals. 114 
 115 
b. Experimental design 116 
 117 
The experimental design is summarized in figure 1. MicroPET and MRI studies were performed on 1, 118 
3, 7 and 30 days after LPS injection. In vitro autoradiography and IHC were performed on 1, 4, 8 and 119 
31 days after LPS injection. There is a difference of 1 day between the in vivo and in vitro experiments 120 
because from the animals that were scanned (PET and MRI) on 3, 7 and 30 days after LPS injection, 121 
one animal was sacrificed 1 day later, respectively on day 4, 8 and 31, for in vitro autoradiography and 122 
IHC to verify microglial proliferation and TSPO expression in the same animal. In that manner the 123 
fluorine-18 was sufficiently decayed and brain slices could be made. On day 1 after LPS injection we 124 
did not observe significant retention of [18F]DPA-714 in the ipsilateral site in the microPET study and 125 
therefore we sacrificed the animals at day 1 after LPS injection for in vitro autoradiography and IHC. 126 
To increase N for in vitro autoradiography and IHC, additional animals were injected with LPS and 127 
sacrificed on day 1, 4, 8 and 31 after LPS injection for in vitro autoradiography and IHC (N≥3 for each 128 
time point and each experiment; Figure 1). IHC and in vitro autoradiography were performed on 129 
adjacent brain slices. Additionally, a pre-treatment study (PK11195 10 mg/kg subcutaneously 60 min 130 
before tracer injection; N=3) and a displacement study (PK11195 5 mg/kg intravenously 30 min after 131 
tracer injection; N=3) were performed at 3 days after LPS injection. All statistical studies were 132 
performed with the unpaired two-tailed t-test, a p value less than 0.05 was considered statistically 133 
significant. Calculations were carried out using GraphPad Prism v5.0 (San Diego, CA). 134 
 135 
 136 
 137 
Figure 1 
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c. Radiosynthesis 138 
The radiotracer [18F]DPA-714 was synthesized as previously described [15] with some small 139 
modifications: most importantly, the semi-preparative HPLC purification was performed using an 140 
ethanol based mobile phase, EtOH:NH4OAc 10 mM pH 7 35:65 V/V. The final preparation containing 141 
less than 10% of EtOH was sterile filtered through a 0.22-µm membrane filter (Millex®-GV, 142 
Millipore, Billerica, USA). [18F]DPA-714 (> 98% radiochemically pure) was obtained with 45-60% 143 
yield (relative to starting [18F]F- radioactivity). The specific activity at end of synthesis ranged from 56 144 
to 148 GBq/µmol. Precursor and reference compound were kindly provided by Prof. Michael Kassiou 145 
(University of Sydney, Australia). 146 
 147 
d. microPET 148 
Imaging experiments were performed on a Focus 220 microPET scanner (Concorde 149 
Microsystems, Knoxville, TN, USA). Rats were injected with about 74 MBq of [18F]DPA-714 via a 150 
tail vein (volume injected <1 mL; specific activity at injection: 51-130 GBq/µmol). During all PET 151 
sessions, animals were kept under gas anesthesia (2.5% isoflurane in O2 at a flow rate of 1 L/min). 152 
List-mode 120-min microPET scans were acquired. Acquisition data were then Fourier rebinned in 27 153 
time frames (4 x 15 s, 4 x 60 s, 5 x 180 s, 8 x 300 s, 6 x 600 s) and reconstructed using maximum a 154 
posteriori iterative reconstruction. The images were spatially aligned to a rat brain [18F]FDG template 155 
in Paxinos coordinates [16] using an affine transformation, allowing the use of a predefined volumes 156 
of interest map. Time-activity curves (TAC) were generated for right and left striatum for each 157 
individual scan using PMOD software (version 3.2; PMOD technologies, Zurich, Switzerland).  158 
Kinetic modeling based on simplified reference tissue model (SRTM) [17] with the 159 
contralateral (left) striatum as a reference region was performed to quantify the uptake difference 160 
between the right and the left striatum.  161 
 162 
 163 
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e. In vitro autoradiography 164 
The rats were sacrificed, brain was removed, rinsed with saline to remove blood, rapidly 165 
frozen in 2-methylbutane (-40 °C) and stored at -20 °C for 24 h. Transversal sections from the brain 166 
were obtained using a cryotome (Shandon cryotome FSE; Thermo Fisher, Waltham, USA), mounted 167 
on adhesive microscope slides (Superfrost Plus; Thermo Fisher) and stored at -20 °C until 168 
autoradiography was performed. Brain slices were dried and preincubated in 50 mM tris-HCl buffer 169 
(pH 7.4) for 10 min at room temperature. Before incubation with [18F]DPA-714, the brain sections 170 
were dried. The brain sections were incubated with 590 kBq of tracer for 10 min. The brain sections 171 
were washed twice for 10 min in 50 mM tris-HCl (pH 7.4) + 0.3% BSA buffer at 4 °C. After a quick 172 
dip in water at 4 °C, the slides were dried. Autoradiograms were obtained by exposing the slides for 5 173 
min to a high performance phosphor storage screen (super-resolution screen; Perkin Elmer, Waltham, 174 
USA). The screens were read using a Cyclone Plus system (Perkin Elmer) and analyzed using 175 
Optiquant software (Perkin Elmer). The radioactivity concentration in the autoradiograms is expressed 176 
in digital light units (DLU)/mm² corrected for background. The data were processed as right striatum 177 
(LPS) to left striatum (saline) ratios (DLU/mm² in right striatum divided by DLU/mm² in left 178 
striatum).  179 
 180 
f. Immunohistochemistry for TSPO and CD68  181 
Cryostat brain sections (adjacent to the slices used for in vitro autoradiography) were fixed 182 
with ethanol, blocked with normal serum and incubated overnight at 4 ºC with a rabbit polyclonal 183 
primary antibody against TSPO (#NBP1-45769 from Novus Biologicals, Littleton, USA) diluted 184 
1:100. Then, sections were incubated for 2 h at room temperature with a secondary anti-rabbit 185 
antibody (Alexa Fluor-488, Molecular Probes, Eugene, USA). Double immunostaining was carried out 186 
with mouse monoclonal antibodies against the microglia/macrophage marker CD68 (ED1, 187 
#MCA341R, Serotec, Kidlington, Oxford) diluted 1:100 or the astroglia marker glial fibrillary acidic 188 
protein (GFAP, #G3893, Sigma) followed by a secondary anti-mouse antibody (Alexa Fluor-546, 189 
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Molecular Probes). Sections were counterstained with To-Pro3 (Invitrogen, Carlsbad, USA) to 190 
visualize the cell nuclei. They were mounted in Mowiol 488 (Sigma–Aldrich) and were observed in a 191 
confocal microscope (Leica TCS, SPC, Wetzlar, Germany).   192 
 193 
g. Magnetic resonance imaging (MRI) 194 
MR images were recorded on a 9.4T/200 Biospec small animal MR system (Bruker Biospin, 195 
Ettlingen, Germany) equipped with a 117-mm inner diameter actively shielded gradient set of 600 196 
mT/m using a 7-cm linearly polarized resonator for transmission and an actively-decoupled dedicated 197 
rat brain surface coil for receiving (Bruker Biospin). Rats were anesthetized with isoflurane in oxygen, 198 
their respiration monitored and body temperature controlled at 37 °C using a water heating circuit (SA 199 
Instruments, Stony Brook, NY, USA). The following MR images were recorded before contrast 200 
injection: (1) 3-dimensional T2-weighted (rapid acquisition with relaxation enhancement, RARE, echo 201 
time (TE) = 11.5 ms, rare factor = 16, repetition time (TR) = 1200 ms, field of view (FOV) = 202 
4x2.6x1.3 cm, matrix = 192x128x64), (2) 3-dimensional T1 –weighted (fast low angle shot, FLASH, 203 
TR= 75 ms, TE= 12 ms, flip angle 15 deg, FOV = 4x2.6x1.3 cm, matrix = 400x260x130), (3) T1 map 204 
(RARE with variable TR (TR=112/227/402/603/837/1118/1470/2655/ 4194/8000 ms, TE=8.7 ms , 205 
rare factor =2, 4 axial slices, FOV= 3.5x3.5 cm, matrix 128x128) and (4) T2 map (Multi slice multi-206 
echo (MSME) sequence with array of 10 echo times starting from 12ms and equally spaced by 12 ms, 207 
TR= 2856 ms, 8 axial slices, FOV=2.5 x 2.5 cm, matrix 256 x 256). For DCE MRI a 3-dimensional 208 
T1–weighted sequence was used (FLASH, TR= 75 ms, TE= 12 ms, flip angle 15 deg, FOV = 209 
4x2.6x1.3 cm, matrix = 400x260x130) with 15 repetitions (1 min per repetition). The contrast agent 210 
(75 µl of 0.05 mmol/ml meglumine gadoterate, Gd-DOTA; Guerbet, Cadoli, Brussels, Belgium) 211 
chased with 100 µl saline, both heated to 37 °C, was manually injected via a catheter placed in a tail 212 
vein after 5 min. 213 
Data acquisition and processing of T1 maps was carried out using Paravision 5.1 (Bruker Biospin) and 214 
DCE data were analyzed using dedicated software (DCE@urLab v1.0, 215 
http://www.die.upm.es/im/archives/DCEurLAB/ [18]). Average dynamic profiles for each time point 216 
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were determined based on manual delineation of the most apparent contrast-enhanced zone and similar 217 
contralateral region. T2 maps were generated by fitting voxelwise the 10 echoes (12, 24, 36, 48, 60, 218 
72, 84, 96, 108 and 120 ms) to a mono-exponential function (eq.1) with a fit goodness R2>0.99 219 
(ImageJ, http://rsb.info.nih.gov/ij/ [19]). 220 
 221 
 222 
Eq.1         M= M0 e-TE/T2 223 
M: voxel intensity  224 
 TE: echo time 225 
 T2: transverse relaxation time 226 
 M0 : initial transverse magnetization 227 
Each map was then smoothed by a median filter with a kernel of 136 µm. Local T2 values were 228 
extracted by placing regions of interest of 13 mm2 centered to the site of injection and on the adjacent 229 
slices. 230 
 231 
3. Results 232 
a. Longitudinal study of LPS model: microPET, in vitro autoradiography and IHC 233 
i. Longitudinal microPET study 234 
A longitudinal microPET study with [18F]DPA-714 was performed to follow up TSPO 235 
expression at 1, 3, 7 and 30 days after LPS injection. Analysis demonstrated that the right striatum in 236 
which LPS was injected showed higher uptake than the left striatum. Binding potentials calculated 237 
with SRTM are presented in table 1 (BPright to left of animals from the combined MRI-PET study are 238 
included in table 1 as the PET scans were performed at the same time points). Statistical calculations 239 
proved a significant difference between 1 and 3, 1 and 7, 3 and 30, 7 and 30 days after LPS injection 240 
(P<0.05). A representative averaged PET image is shown in figure 6b. 241 
 242 
Table 1 
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ii. In vitro autoradiography 243 
Analysis of the in vitro autoradiography results showed higher tracer uptake in the LPS 244 
injected striatum compared to the saline injected striatum. The signal decreased gradually in time with 245 
the highest signal at 4 days after LPS injection (figure 2a-c). The right to left ratios at 1, 4, 8 and 31 246 
days after LPS injection were 2.1±0.6, 5.1±1.1, 4.1±0.9 and 3.0±1.1, respectively (figure 1e). 247 
Statistical calculations proved a significant difference between 1 and 4, 1 and 8, 4 and 31, 8 and 31 248 
days after LPS injection (P<0.05). We performed a blocking study using PK11195 (20 µM) as a 249 
blocking agent on brain slices 3 days after LPS injection and PK11195 significantly reduced 250 
[18F]DPA-714 binding (P<0.0001; figure 2f-g). 251 
 252 
  253 
iii. Immunohistochemistry (CD68, GFAP and TSPO) 254 
IHC showed immunoreactivity for TSPO and CD68 (a marker of myeloid cells expressed by reactive 255 
microglia and macrophages) at 4, 8 and 31 days after LPS injection. The intensity of CD68 256 
immunoreactivity was higher in the ipsilateral than the contralateral hemisphere indicative of 257 
microglia activation by LPS. In the ipsilateral striatum, highly CD68+ immunoreactive cells were 258 
more abundant at 4 and 8 days and decreased at day 31 (figure 3). Immunoreactivity for TSPO was not 259 
detected in the contralateral hemisphere (figure 3f) but was found in the ipsilateral hemisphere located 260 
in CD68+ cells (figure 3a-e). Notably, TSPO expression was detected at day 4 and 8 after LPS 261 
injection, but not at day 1. At day 31, TSPO staining was still detected but was less prominent than at 262 
previous time points after LPS injection. At day 4, TSPO staining was detected in ramified microglia 263 
(arrows figure 3a) and in isolated amoeboid cells with macrophage-like morphology (figure 3b) that 264 
could correspond to reactive microglia or infiltrated macrophages. TSPO+ cells with amoeboid shape 265 
predominated at day 8 (Fig. 3c, d). At day 31, faint TSPO immunoreactivity was detected in ramified 266 
CD68+ cells (figure 3e). TSPO immunoreactivity was mainly located in perivascular 267 
microglia/macrophages suggesting that the vasculature is a target of the inflammatory reaction after 268 
intracerebral LPS administration. In addition, we observed faint TSPO immunoreactivity in regions 269 
Figure 2 
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surrounding the lesion site (including the corpus callosum and cortical regions) in cells with stellate 270 
morphology that could correspond to reactive astrocytes. To confirm this possibility we carried out 271 
double immunofluorescence with an antibody against the astroglia marker GFAP (figure 4). While the 272 
cells with the highest TSPO immunoreactivity were GFAP negative (figure 4a, c), GFAP positive cells 273 
located in the periphery of the LPS injection site showed low TSPO immunoreactivity at days 4, 8 and 274 
31 (figure 4b, d-f) suggesting that reactive astrocytes can express a low level of TSPO.   275 
 276 
 277 
b. Pre-treatment and displacement microPET study 278 
In order to determine whether in vivo binding of [18F]DPA-714 is specific for TSPO and 279 
reversible, we performed a pre-treatment study (PK11195 10 mg/kg subcutaneously 60 min before 280 
tracer injection; N=3) and a displacement study (PK11195 5 mg/kg intravenously 30 min after tracer 281 
injection; N=3) (figure 3). Figure 5a shows a microPET scan at 3 days after LPS injection. The TAC 282 
of the pre-treatment study (figure 5b) shows that binding was not blocked completely although there 283 
was a decrease in tracer uptake in the LPS injected site compared to the TAC without pre-treatment 284 
(figure 3a). IV injection of PK11195 (5 mg/kg) could fully displace the binding of [18F]DPA-714 in 285 
the LPS injected site but also in the control (saline injected) site some [18F]DPA-714 binding is 286 
displaced (figure 5c). 287 
 288 
 289 
c. MRI 290 
Considering that tracer uptake may be influenced by BBB integrity, we used DCE MRI to 291 
determine the level of BBB breakdown induced by the LPS or saline injection. DCE MRI 292 
demonstrated loss of BBB integrity at the LPS injection site but not in the contralateral saline injection 293 
site (figure 6a). The contrast enhancement was most apparent at day 1, reduced at day 3 and 7 and not 294 
Figure 3 
Figure 4 
Figure 5 
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observable 1 month after LPS injection (figure 7). Accordingly, the differences between the time 295 
points for the group averaged DCE MRI signal intensity time profiles from the striatal region with 296 
LPS injection showed a similar response. Striatal T2 values of the LPS injected side were higher 297 
compared to the contralateral side (saline injected) for each time point with a maximal T2 value 298 
reached between 3 and 7 days after LPS injection (figure 8). These data are consistent with the 299 
longitudinal PET and autoradiography data. 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
Figure 6 
Figure 7 
Figure 8 
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4. Discussion 316 
This LPS model is a very interesting animal model from a quantification point of view since it 317 
has the advantage that neuroinflammation is induced locally around the stereotactic injection site and 318 
each animal can be used as its own control using the contralateral hemisphere. In vivo PET imaging 319 
showed the highest tracer uptake at 3 days after LPS injection and this signal remained quite stable 320 
until 7 days after LPS injection. Afterwards, the signal gradually decreased as determined by 321 
calculating BPright to left using the simplified reference tissue model with the contralateral striatum as a 322 
reference region (table 1). BPright to left were also calculated in a slightly different LPS model (unilateral 323 
injection of 1-10 µg LPS; saline injected in separate animals as control; different animal strain; LPS 324 
from different E. coli strains) using [18F]GE-180 and [11C]PK11195 as radioligands by Dickens et al 325 
[14]. Additionally, in this study, the animals were scanned at 16 h after LPS injection while the earliest 326 
time point in our study was 24 h after LPS injection hampering a reliable comparison of both studies. 327 
Interestingly, both studies confirmed an early (16-24 h) increase of TSPO expression after LPS 328 
injection. Boutin et al. [6] compared [18F]DPA-714 and [11C]PK11195 in a rat stroke model. Although 329 
the BP (calculated with SRTM) seemed comparable for [18F]DPA-714 in both animal models (stroke 330 
model: 3.1; LPS model 3.0), the standard deviation was higher for the stroke model (stroke model: 3.0; 331 
LPS model 0.3). This variability in animal models of neuroinflammation needs to be considered when 332 
comparing different tracers in the same model. Preferably the same animal is scanned with different 333 
tracers and the scans need to be performed within a limited time window because of the longitudinal 334 
variation in neuroinflammation as observed in this study. 335 
In order to verify specific and reversible binding of [18F]DPA-714 in this specific animal 336 
model, displacement and pre-treatment studies were performed. [18F]DPA-714 binding in the lesion 337 
site could partly be blocked by pre-treatment with PK11195 (10 mg/kg subcutaneously 60 min before 338 
tracer injection). Subcutaneous administration was chosen because of the slow pharmacokinetics and 339 
thus slow but rather constant release of the blocking agent in blood. IV injection has fast kinetics but 340 
dissociation from the target at the time of tracer injection might occur. Probably the dose administered 341 
of PK11195 was not high enough for complete blocking via subcutaneous route. Interestingly, IV 342 
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injection (fast pharmacokinetics) of 5 mg/kg PK11195 30 min after tracer injection could fully 343 
displace the binding of [18F]DPA-714 in the LPS injected site but also in the saline injected site some 344 
[18F]DPA-714 binding is displaced which is probably due to basal TSPO expression in brain. These 345 
results are in line with the displacement study performed by Moon et al. in a more comparable LPS 346 
model than the LPS model of Dickens et al. (unilateral injection of 50 µg LPS though different rat 347 
strain; contralateral striatum as control but no saline injection) using different TSPO tracers 348 
([18F]fluoromethyl-PBR28 and [11C]PBR28), although displacement in non-injected striatum was less 349 
than observed in our study [13,14].  350 
In vitro autoradiography showed higher tracer uptake in the LPS injected striatum compared to 351 
the saline injected striatum. This higher uptake was already observed at 1 day after LPS injection and 352 
increased to the most intense and quite stable signal between 4 and 8 days after LPS injection after 353 
which the signal gradually decreased in time as determined by calculating the right to left ratios. The 354 
presence of PK11195 (20 µM) completely blocked [18F]DPA-714 binding, suggesting that the 355 
observed [18F]DPA-714 binding is TSPO specific. In vitro but not in vivo retention of [18F]DPA-714 356 
uptake was noticed in white matter (corpus callosum) which was also observed by Dickens et al. using 357 
[18F]GE-180 [14].     358 
The in vitro data confirmed the in vivo data by a positive correlation between BPright-to-left (in 359 
vivo microPET) and right-to-left ratios (in vitro autoradiography). Another important validation in pre-360 
clinical PET studies is the confirmation of expression of the target protein by IHC. The purpose of the 361 
IHC was the qualitative assessment of TSPO expression and to identify the cells expressing TSPO. 362 
TSPO expression at the cellular level was confirmed by IHC using antibodies against TSPO and 363 
CD68. CD68 positive myeloid cells were abundant at 4 and 8 days after LPS injection and this 364 
reaction was reduced at 31 days. TSPO immunoreactive cells were seen at 4 and 8 days in amoeboid 365 
CD68+ cells compatible with reactive microglia or perivascular macrophages. However, at day 4, a 366 
comparatively fainter TSPO immunoreactivity was detected in CD68+ ramified microglia cells 367 
compatible with early stages of microglia activation. Therefore, these CD68+ reactive ramified 368 
microglia cells that were more prominent at day 4 than day 8 could be responsible for the higher 369 
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[18F]DPA-714 binding found at day 4 compared to day 8 when most TSPO+ cells had amoeboid 370 
morphology. The [18F]DPA-714 binding site in the TSPO protein likely differs from the binding sites 371 
of the polyclonal anti-TSPO antibody. During the dynamic process of microglia activation, it is 372 
possible that the availability of those binding sites changes due to putative interactions of TSPO with 373 
other proteins that could mask certain binding sites. Further studies of protein-protein interactions 374 
along time might help to elucidate the relevant TSPO binding sites and their availability in relation to 375 
the stage of microglial activation. No CD68 or TSPO immunoreactivity was observed in the 376 
contralateral site. In addition, we detected faint TSPO immunoreactivity in astrocytes in regions 377 
surrounding the injection site, but it is currently unknown whether low TSPO expression in reactive 378 
astrocytes contributed to the PET signal.  379 
We performed MRI studies to be certain that tracer uptake was not due to BBB disruption but 380 
to upregulation of TSPO expression induced by the LPS injection. DCE MRI indicated maximal BBB 381 
breakdown at day 1 after LPS injection with progressive restoration and full recovery at 1 month after 382 
LPS injection. These data suggest that tracer uptake was due to TSPO binding as no tracer uptake was 383 
seen at day 1 after LPS injection when BBB breakdown was at maximum. The fact that in vivo 384 
microPET data (possible influence of BBB integrity on tracer uptake) and in vitro autoradiography 385 
data (no influence of BBB on tracer uptake) were positively correlated, suggested tracer uptake during 386 
in vivo PET imaging was not due to BBB disruption. Conversely, BBB breakdown will favour 387 
vascular and perivascular inflammation and might contribute to microglia/macrophage activation 388 
around the vasculature. The quantification of the striatal transverse relaxation (T2) showed a nice 389 
correlation with the PET and autoradiography imaging suggesting that T2 in this case may reflect the 390 
underlying inflammation process. 391 
The characterization of the LPS model with an established neuroinflammation tracer is of great 392 
importance as we are developing and evaluating new radiotracers for potential new targets upregulated 393 
during neuroinflammation. The longitudinal variation in neuroinflammation (as measured in this 394 
study) has to be taken into account when comparing different tracers. The LPS model is useful for first 395 
screening of newly developed tracers because of the easy design and the robust, unilateral 396 
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inflammatory reaction allowing the use of the contralateral region as control. The radioligands with the 397 
most potential can be selected for further screening in more clinical relevant disease models 398 
accelerating the translation to human PET studies. Additionally, this animal model is suitable to 399 
evaluate (new) anti-inflammatory therapy in an initial preclinical setting. This preliminary screening 400 
can select the most potential compounds for further evaluation and accelerate the translation of the 401 
therapy to humans.  402 
This model will now be used to evaluate radioligands for other targets upregulated during 403 
neuroinflammation such as the CB2 and P2X7 receptor thereby accelerating the PET radioligand 404 
development for in vivo imaging of neuroinflammation [3].  405 
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TABLES 488 
 489 
TABLE 1: Kinetic modeling. Binding potential ± SD in right striatum obtained by SRTM with left 490 
striatum as reference tissue 491 
Left striatum as reference tissue 
Days after LPS injection 1 (n=3) 3 (n=5) 7 (n=4) 30 (n=3) 
Binding potential 0.4 ± 0.1 3.0 ± 0.3 2.5 ± 0.6 0.9 ± 0.2   
 492 
 493 
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 500 
 501 
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 504 
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FIGURE CAPTIONS 511 
 512 
FIGURE 2. Experimental design. Following experiments were performed: 1 day after LPS injection, 513 
microPET (n=3), MRI (n=6), in vitro autoradiography and IHC (n=3); 3 days after LPS injection 514 
microPET (n=5) and MRI (n=5); 4 days after LPS injection, in vitro autoradiography and IHC (n=3); 7 515 
days after LPS injection, microPET (n=4) and MRI (n=6); 8 days after LPS injection, in vitro 516 
autoradiography and IHC (n=4); 30 days after LPS injection, microPET (n=3) and MRI (n=4); 31 days 517 
after LPS injection, in vitro autoradiography and IHC (n=4). ARX: in vitro autoradiography; IHC: 518 
immunohistochemistry 519 
 520 
 521 
FIGURE 2. In vitro autoradiography of brain slices of rat LPS model using [18F]DPA-714. 522 
Transversal brain sections made of rats, respectively 4 days (a), 8 days (b) and 31 days (c) after LPS 523 
injection, incubated with [18F]DPA-714. LPS was injected in the right striatum and the LPS-induced 524 
TSPO expression is clearly visualized by [18F]DPA-714. [18F]DPA-714 binding could be blocked with 525 
20 µM PK11195 3 days after LPS injection (> 96%) (d-e). The signal is the highest in the LPS 526 
injected striatum 4 days after LPS injection and the right to left (R/L) ratio decreases gradually in time 527 
(f). 528 
 529 
FIGURE 3. IHC on LPS model: TSPO and CD68. TSPO is expressed in CD68+ reactive 530 
microglia/macrophages. Images show TSPO (green), CD68 (red), the nuclei labelled with TO-PRO3 531 
(blue), and the merged staining in sections taken from the ipsilateral hemisphere at day 4 (a, b), 8 (c,d) 532 
and 31 (e) after LPS administration. TSPO is mostly expressed in CD68+ cells in the ipsilateral 533 
hemisphere (arrows in a-e) but is not detected in the contralateral hemisphere (f). Bar scale: 10 µm. 534 
 535 
FIGURE 4. IHC on LPS model: TSPO and GFAP. Faint TSPO expression is observed in reactive 536 
astrocytes. Images show TSPO (green), GFAO (red), the nuclei labelled with TO-PRO3 (blue), and 537 
the merged staining in sections taken from the ipsilateral hemisphere at day 4 (a, b), 8 (c-e) and 31 (f) 538 
after LPS administration. Cells strongly immunoreactive for TSPO are not GFPA positive (arrows in 539 
a-c). However, reactive astrocytes located at the periphery of the injection site in the ipsilateral 540 
hemisphere show a faint TSPO immunoreactivity 8 and 31 days after LPS administration (arrows in d-541 
f). Bar scale: 10 µm. 542 
 543 
FIGURE 5. MicroPET studies with [18F]DPA-714 in a LPS rat model. a: TAC of a microPET scan 544 
at 3 days after LPS injection; b: TAC of a microPET study after pre-treatment with PK11195 545 
(subcutaneously 10 mg/kg 60 min before tracer injection) at 3 days after LPS injection; c: TAC of a 546 
displacement microPET study with PK11195 (intravenously 5 mg/kg 30 min after tracer injection) at 3 547 
days after LPS injection. Animals were kept under gas anesthesia (2.5% isoflurane in O2 at a flow rate 548 
of 1 L/min). Rats were injected with about 74 MBq of [18F]DPA-714 via a tail vein. 549 
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FIGURE 6. In vivo DCE MRI and microPET study of one representative animal in time. a: 550 
dynamic signal intensity (SI) changes from the LPS or saline injection zones. BBB disruption near the 551 
LPS injection site (right hemisphere) is evident at 1 day and reduced at 3 and 7 days. No contrast 552 
enhancement is seen 1 month after the LPS injection or near the saline injection site (left hemisphere; 553 
all time points). b: averaged microPET images of the whole scan (120 min) after [18F]DPA-714 554 
injection were acquired. Data were normalized for injected activity and body weight of the animal 555 
(SUV). Animals were kept under gas anesthesia (2.5% isoflurane in O2 at a flow rate of 1 L/min). Rats 556 
were injected with about 74 MBq of [18F]DPA-714 via a tail vein. 557 
 558 
FIGURE 7. In vivo DCE MRI. Dynamic signal intensity (SI) changes from the LPS or saline 559 
injection zones resulting from the Gd-DOTA injection at the different time points 1 day, 3 days, 1 560 
week and 1 month. a: BBB disruption near the LPS injection site (right hemisphere) is present at 1, 3 561 
and 7 days. b: No contrast enhancement is seen at 1 month after the LPS injection or near the saline 562 
injection site (left hemisphere; all time points; CA: contrast agent).   563 
FIGURE 8. Parametric T2 maps. a: Parametric T2 maps at day 1, 3, 7 and 30 of a representative 564 
animal with injection of 50 µg LPS in the right striatum (white arrow) and saline on the left side. T2 565 
maps are all scaled from 30 to 70 ms. b: Striatal T2 values, data are expressed as mean ± SD. Day 1: N 566 
= 3, Day 3: N = 5, Day 7: N = 6, Day 30: N = 5. 567 
 568 
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